Achieve Life Sciences, Inc. Revenue
Achieve Life Sciences, Inc. (ACHV) reported Revenue of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-13.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2020-03-13
- Achieve Life Sciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $0.00.
- Achieve Life Sciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-13 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |